^
    Back
    Association details:
    Biomarker:PIK3CA exon 20 mutation + HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    ESMO.org
    Title:

    ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer†

    Excerpt:
    A proposed treatment algorithm for the management of hormone receptor (HR)-positive, HER2-negative MBC...Alpelisib/fulvestrant is a treatment option for patients with PIK3CA-mutant tumours (in exons 7, 9 or 20), prior exposure to an AI (± CDK4/6 inhibitors) and appropriate HbA1c levels...
    Secondary therapy:
    fulvestrant
    DOI:
    https://doi.org/10.1016/j.annonc.2021.09.019.
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    N Engl J Med
    Title:

    Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer

    Excerpt:
    Treatment with alpelisib–fulvestrant prolonged progression-free survival among patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer...kinase domains of PI3K (corresponding to exons 7, 9, and 20, respectively).
    Secondary therapy:
    fulvestrant
    DOI:
    10.1056/NEJMoa1813904
    Trial ID:
    SOLAR-1